Drug utilization evaluation of ceftazidime-avibactam in a tertiary care hospital

Varagani Tejaswini; Madesi Harshini Sri; Syeda Mahera Samreen; Chodi Brundasree; Jorige Archana

doi:10.18203/2394-6040.ijcmph20242175

Authors

Varagani Tejaswini Department of Pharmacy Practice, RBVRR Women’s College of Pharmacy, Baghlingmpally Cross Road, Barkatpura, Hyderabad, Telangana, India
Madesi Harshini Sri Department of Pharmacy Practice, RBVRR Women’s College of Pharmacy, Baghlingmpally Cross Road, Barkatpura, Hyderabad, Telangana, India
Syeda Mahera Samreen Department of Pharmacy Practice, RBVRR Women’s College of Pharmacy, Baghlingmpally Cross Road, Barkatpura, Hyderabad, Telangana, India
Chodi Brundasree Department of Pharmacy Practice, RBVRR Women’s College of Pharmacy, Baghlingmpally Cross Road, Barkatpura, Hyderabad, Telangana, India
Jorige Archana Department of Pharmacy Practice, RBVRR Women’s College of Pharmacy, Baghlingmpally Cross Road, Barkatpura, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20242175

Keywords:

Antimicrobial resistance, Aztreonam, Ceftazidime-avibactam

Abstract

Background: The World Health Organization considers antimicrobial resistance a major global threat, and ceftazidime-avibactam (CAZ-AVI) is a treatment for multidrug-resistant Gram-negative infections. The FDA approved its use in 2015 for infections with limited treatment options.

Methods: A retrospective study was conducted in a hospital in India to analyse the use of CAZ-AVI formulation in patients. Data was collected from electronic records and included information on patient demographics, clinical and microbiological profiles, antibiotic treatment, and patient outcomes for those in the ICU.

Results: A total of 110 patients were included in the study. On assessing the results of this study, it was found that, the median age of population who received CAZ-AVI was 63 years and hypertension, diabetes mellitus were the common comorbidities present in the patients. Out of 110 subjects, 66 (60%) patients were started with a high-end antibiotic as an empirical therapy. While analysing the resistance pattern, it was found that 22 (20%) were resistant and 84 (76%) of the study subjects were sensitive to ceftazidime-avibactam. There was higher clinical success for BSI, CUTI, VAP amongst the indications of CAZ-AVI and combination of CAZ-AVI with aztreonam has given the most successful treatment outcome. The combination of CAZ-AVI with one or two high end antibiotics was observed as a common clinical practice.

Conclusions: The analysis of results showed encouraging clinical cure rates. Our study results suggest that ceftazidime-avibactam could be an effective standard therapy for managing MDR Gram -negative organisms.

Metrics

Metrics Loading ...

References

Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al‐Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, et al. Antibiotic resistance: the challenges and some emerging strategies for tackling a global menace. J Clin Lab Analysis. 2022;36(9):e24655.

Caliskan-Aydogan O, Alocilja EC. A review of carbapenem resistance in Enterobacterales and its detection techniques. Microorganisms. 2023;11(6):1-26.

Yang P, Li Y, Wang X, Chen N, Lu X. Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis. BMJ Open. 2023;13(5):1-8.

Arer V, Kar D. Biochemical exploration of β-lactamase inhibitors. Front Genet. 2023;13(January):1-15.

EmA. Zavicefta, INN-avibactam and ceftazidime. Zavicefta, INN-avibactam and ceftazidime profile. Available from: https://www.ema.europa.eu/en/ documents/product-information/zavicefta-epar-product-information_en.pdf. Accessed on 13 January 2024.

Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G, Irani P, et al. The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study. Infect Dis Ther. 2023;12(3):891-917.

Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10(4):1989-2034.

Xiao S, Fu Q, Miao Y, Zhao M, Lu S, Xu J, et al. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. Front Microbiol. 2023;14:1198926.

Wang W, Wang R, Zhang Y, Zeng L, Kong H, Bai X, et al. Ceftazidime-avibactam as salvage therapy in pediatric liver transplantation patients with Infections caused by carbapenem-resistant Enterobacterales. Infect Drug Resist. 2022:3323-32.

Huang X, Han M, Jin F, Zhu Z, Zhang H. Analysis of a refractory case of pediatric meningitis caused by klebsiella pneumoniae co-resistant to carbapenems and polymyxins. Infect Drug Resist. 2022;15(September):5309-13.

Guedes M, Duro R, Fonseca T, Abreu I, Rocha-Pereira N. Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline. IDCases. 2020;20:e00745.

Hakeam HA, Alsahli H, Albabtain L, Alassaf S, Al Duhailib Z, Althawadi S. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1-7.

Hoşbul T, Aydogan CN, Kaya S, Bedir O, Gümral R, Albay A. In vitro activity of ceftazidime-avibactam and colistin against carbapenem-resistant Klebsiella pneumoniae clinical isolates. Mikrobiyol Bul. 2022;56(2):218-29.

Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: An evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13-25.

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023:ciad428.

Venkatesh S, Chauhan LS, Gadpayle AK, Jain TS, Ghafur A, Wattal C. National treatment guidelines for antimicrobial use in infectious diseases. India: National Centre for Disease Control, MOHFW, Government of India; 2011:1-64.

Karaiskos I, Daikos GL, Gkoufa A, Adamis G, Stefos A, Symbardi S, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother. 2021;76(3):775-83.

Nagvekar V, Shah A, Unadkat VP, Chavan A, Kohli R, Hodgar S, et al. Clinical outcome of patients on ceftazidime–avibactam and combination therapy in carbapenem-resistant Enterobacteriaceae. Indian J Crit Care Med. 2021;25(7):780.